Hoth Therapeutics Stock Current Liabilities
| HOTH Stock | USD 0.82 0.02 2.38% |
Hoth Therapeutics fundamentals help investors to digest information that contributes to Hoth Therapeutics' financial success or failures. It also enables traders to predict the movement of Hoth Stock. The fundamental analysis module provides a way to measure Hoth Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Hoth Therapeutics stock.
The current Total Current Liabilities is estimated to decrease to about 641.9 K. The current Non Current Liabilities Total is estimated to decrease to about 25 K. Hoth | Current Liabilities |
Hoth Therapeutics Company Current Liabilities Analysis
Hoth Therapeutics' Current Liabilities is the company's short term debt. This usually includes obligations that are due within the next 12 months or within one fiscal year. Current liabilities are very important in analyzing a company's financial health as it requires the company to convert some of its current assets into cash.
Current Hoth Therapeutics Current Liabilities | 312.22 K |
Most of Hoth Therapeutics' fundamental indicators, such as Current Liabilities, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Hoth Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Hoth Current Liabilities Driver Correlations
Understanding the fundamental principles of building solid financial models for Hoth Therapeutics is extremely important. It helps to project a fair market value of Hoth Stock properly, considering its historical fundamentals such as Current Liabilities. Since Hoth Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Hoth Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Hoth Therapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
Hoth Current Liabilities Historical Pattern
Today, most investors in Hoth Therapeutics Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Hoth Therapeutics' growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's current liabilities growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Hoth Therapeutics current liabilities as a starting point in their analysis.
Hoth Therapeutics Current Liabilities |
| Timeline |
Current liabilities appear on the company's balance sheet and include all short term debt accounts, accounts and notes payable, accrued liabilities as well as current payments due on the long-term loans. One of the most useful applications of Current Liabilities is the current ratio which is defined as current assets divided by its current liabilities. High current ratios mean that current assets are more than sufficient to pay off current liabilities.
| Competition |
Hoth Total Current Liabilities
Total Current Liabilities |
|
In accordance with the recently published financial statements, Hoth Therapeutics has a Current Liabilities of 312.22 K. This is 99.98% lower than that of the Pharmaceuticals sector and 99.94% lower than that of the Health Care industry. The current liabilities for all United States stocks is 100.0% higher than that of the company.
Hoth Current Liabilities Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Hoth Therapeutics' direct or indirect competition against its Current Liabilities to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Hoth Therapeutics could also be used in its relative valuation, which is a method of valuing Hoth Therapeutics by comparing valuation metrics of similar companies.Hoth Therapeutics is currently under evaluation in current liabilities category among its peers.
Hoth Therapeutics Current Valuation Drivers
We derive many important indicators used in calculating different scores of Hoth Therapeutics from analyzing Hoth Therapeutics' financial statements. These drivers represent accounts that assess Hoth Therapeutics' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Hoth Therapeutics' important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 56.7M | 29.3M | 14.7M | 9.3M | 4.9M | 4.7M | |
| Enterprise Value | 55.0M | 26.7M | 6.2M | 2.9M | (4.3M) | (4.1M) |
Hoth Fundamentals
| Return On Equity | -0.83 | ||||
| Return On Asset | -0.46 | ||||
| Current Valuation | (2.19 M) | ||||
| Shares Outstanding | 6.9 M | ||||
| Shares Owned By Insiders | 0.92 % | ||||
| Shares Owned By Institutions | 5.30 % | ||||
| Number Of Shares Shorted | 620.78 K | ||||
| Price To Earning | (7.16) X | ||||
| Price To Book | 0.77 X | ||||
| EBITDA | (153.15 K) | ||||
| Net Income | (7.85 M) | ||||
| Cash And Equivalents | 11.62 M | ||||
| Cash Per Share | 9.02 X | ||||
| Total Debt | 55.16 K | ||||
| Debt To Equity | 2.01 % | ||||
| Current Ratio | 15.74 X | ||||
| Book Value Per Share | 1.09 X | ||||
| Cash Flow From Operations | (8.45 M) | ||||
| Short Ratio | 0.44 X | ||||
| Earnings Per Share | (1.27) X | ||||
| Target Price | 4.5 | ||||
| Beta | 0.84 | ||||
| Market Capitalization | 5.8 M | ||||
| Total Asset | 9.52 M | ||||
| Retained Earnings | (52.94 M) | ||||
| Working Capital | 8.75 M | ||||
| Current Asset | 448.84 K | ||||
| Current Liabilities | 312.22 K | ||||
| Net Asset | 9.52 M |
About Hoth Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Hoth Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Hoth Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Hoth Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
When determining whether Hoth Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Hoth Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Hoth Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Hoth Therapeutics Stock:Check out Hoth Therapeutics Piotroski F Score and Hoth Therapeutics Altman Z Score analysis. For more detail on how to invest in Hoth Stock please use our How to Invest in Hoth Therapeutics guide.You can also try the My Watchlist Analysis module to analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Hoth Therapeutics. If investors know Hoth will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Hoth Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.27) | Return On Assets (0.46) | Return On Equity (0.83) |
The market value of Hoth Therapeutics is measured differently than its book value, which is the value of Hoth that is recorded on the company's balance sheet. Investors also form their own opinion of Hoth Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Hoth Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Hoth Therapeutics' market value can be influenced by many factors that don't directly affect Hoth Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Hoth Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Hoth Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Hoth Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.